Inventiva (NASDAQ:IVA - Get Free Report) had its price objective dropped by Stifel Nicolaus from $20.00 to $17.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a "buy" rating on the stock.
IVA has been the subject of a number of other reports. HC Wainwright lowered their price target on Inventiva from $14.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, October 15th. UBS Group began coverage on shares of Inventiva in a report on Tuesday, November 12th. They set a "neutral" rating and a $3.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $13.25.
Read Our Latest Stock Analysis on Inventiva
Inventiva Stock Performance
Shares of Inventiva stock traded down $0.04 during trading on Friday, reaching $2.62. The company had a trading volume of 18,019 shares, compared to its average volume of 27,155. Inventiva has a fifty-two week low of $1.53 and a fifty-two week high of $4.75. The firm's fifty day moving average is $2.37 and its 200-day moving average is $2.65.
Hedge Funds Weigh In On Inventiva
An institutional investor recently bought a new position in Inventiva stock. Virtu Financial LLC purchased a new position in shares of Inventiva S.A. (NASDAQ:IVA - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 10,490 shares of the company's stock, valued at approximately $38,000. Hedge funds and other institutional investors own 19.06% of the company's stock.
About Inventiva
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Featured Articles
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
